Health ❯ Healthcare ❯ Pharmaceuticals ❯ Drug Development

Antibody-Drug Conjugates

Padcev–Keytruda Cuts Recurrence and Death Risk in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

The companies plan regulatory discussions after presenting the late-stage results at ESMO.

Datroway Extends Survival Over Chemotherapy in First-Line TNBC Ineligible for Immunotherapy

FDA Grants Priority Review for Enhertu Plus Pertuzumab in First-Line HER2-Positive Metastatic Breast Cancer

Iza-Bren Plus Osimertinib Delivers 100% Response in Small First-Line EGFR-Mutant NSCLC Cohort

Padcev and Keytruda Combo Extends Survival in Bladder Cancer Trial